Society | First-line therapy | Second-line therapy |
Cancer Care Ontario Program, 2005 & 2010 [6] | Platinum-based doublet chemotherapy | Docetaxel (option: pemetrexed) followed by erlotinib |
European Lung Cancer Working Party (ELCWP), 2006 [7] | Cisplatin-based chemotherapy with one of the regimens shown to be effective | Docetaxel (if not already administered as first-line treatment) given on a 3-weekly schedule at a dosage of 75 mg·m−2 |
American College of Chest Physicians (AACP), 2007 [8] | Platinum-based chemotherapy with a new single agent (ECOG PS 0-1) | Should be offered if good PS |
American Society of Clinical Oncology (ASCO), 2009 [9] | Two-drugs platinum-based combination regimen. Clinicians may consider the addition of bevacizumab (based on exclusion criteria of the registration trial) or cetuximab (in patients with an EGFR positive tumour as measured by immunohistochemistry | Docetaxel, erlotinib, gefitinib, or pemetrexed |
German Respiratory Society and the German Cancer Society, 2010 [10] | Cisplatin-based combination chemotherapy | Docetaxel, pemetrexed (non-squamous carcinoma) and erlotinib |
PS: performance status